Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Miach Orthopaedics Names Stephen Wohlert, PhD, Vice President of Manufacturing


Miach Orthopaedics, Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, today announced that Stephen Wohlert, PhD, has joined the company as vice president of manufacturing. Dr. Wohlert will lead Miach's manufacturing and platform innovation efforts for the Bridge-Enhanced® ACL Repair (BEAR®) Implant, an investigational device designed for anterior cruciate ligament (ACL) repair.

"Stephen is an experienced leader with a successful track record of transferring concepts to product development and commercialization," said Martha Shadan, president and CEO, Miach Orthopaedics. "His unique expertise in collagen processes will be invaluable not only for overseeing manufacturing of the BEAR Implant as a treatment for ACL repair, but also for further innovating the platform technology."

Dr. Wohlert brings more than 15 years of experience in medical device and over-the-counter drug concept and product development. Most recently he served as director of research and development at Professional Disposable International (PDI) in Montvale, New Jersey. Additional experience includes director of research and development positions at Medtronic/Covidien in Trévoux, France, and North Haven, Connecticut, and project leader at Ethicon Norderstedt in Germany. He holds a doctorate degree in chemistry from the Technical University of Aachen in Germany and a master's degree in chemistry from Christian Albrecht University of Kiel in Germany.

About ACL Injuries and the BEAR® Implant

Every year, approximately 400,000 anterior cruciate ligament (ACL) injuries occur in the U.S. Without treatment, the ACL does not heal, resulting in ACL reconstruction surgery being one of the most common orthopaedic procedures in the U.S. Miach Orthopaedics' new Bridge-Enhanced® ACL Repair (BEAR®) technology is a proprietary bio-engineered bridging scaffold used to facilitate healing of the torn ACL. It is hoped this new technology will restore more normal anatomy and function of the knee, and thus enable a higher percentage of patients to get back to activities they enjoy. The BEAR II pivotal study completed enrollment, and the BEAR Implant is only available in ongoing FDA-approved clinical trials.

About Miach Orthopaedics, Inc.

Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, dedicated to developing bio-engineered surgical implants for connective tissue repair. The company's initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable alternative to conventional ACL reconstruction for patients who have sustained an ACL injury. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children's Hospital Department of Orthopaedic Surgery with initial research funding provided by the NFL Players Association, Boston Children's Hospital and the National Institutes of Health. For more information on Miach Orthopaedics and its products, visit www.miachortho.com and follow the company on Twitter and LinkedIn.


These press releases may also interest you

at 10:00
Spherix Incorporated today announced that on February 21, 2020, a special committee of the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 70,000 shares of Hoth Therapeutics, Inc. ("Hoth")...

at 09:10
Using online estimates will tell the policyholders if they still pay fair prices for their coverage. Comparing prices from multiple companies will help drivers have a better view of the market. When shopping online, it is important to follow the next...

at 09:00
On February 18, 2020, the second online course of ALLPCB, Four-Step Method of WeChat Marketing, arrived as scheduled. Led by the director of Training Center, jointly researched by Training Center and Sales Center, this course aims to provide sales...

at 08:26
Phoenix Contact, a digital industrial company is set to participate at the upcoming Middle East Energy Exhibition (formerly known as Middle East Electricity), the global energy platform. The Phoenix Contact stand will be located at booth number 6A10...

at 07:00
From RSA 2020, Wallarm has released an expanded set of parsers, detection of API-specific vulnerabilities and API schema analysis for gRPC and GraphQL. With Wallarm context-specific protection is delivered both for externally-facing APIs and for...

at 06:49
Cellcom Israel Ltd. (the "Company") announced today that Mr. Ami Erel, the Company's Chairman of the Board of Directors, informed the Company of his resignation from the board of directors, effective March 1, 2020. About Cellcom Israel Cellcom...



News published on 21 january 2020 at 09:05 and distributed by: